Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials (Journal of Nanobiotechnology, (2023), 21, 1, (478), 10.1186/s12951-023-02236-z)

Jimin Ren, Richard B. Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Karen S. Ho, Peter V. Sguigna, Robert Glanzman, Michael T. Hotchkin, Richard B Dewey, Benjamin M. Greenberg

Neurology & Neurotherapeutics
Pediatrics
Neurology & Neurotherapeutics - NE Multiple Sclerosis Section

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials (Journal of Nanobiotechnology, (2023), 21, 1, (478), 10.1186/s12951-023-02236-z)'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials (Journal of Nanobiotechnology, (2023), 21, 1, (478), 10.1186/s12951-023-02236-z)

Fingerprint

Engineering & Materials Science

Medicine & Life Sciences

Chemical Compounds